Mode
Text Size
Log in / Sign up
Phase 3 N=713 Randomized Treatment

Heart And Lung Failure - Pediatric INsulin Titration Trial

Heart Failure · Respiratory Failure

Enrolled (actual)
713
Serious AEs
3.6%
Results posted
Dec 2017
Primary outcome: Primary: ICU-Free Days — 20; 19.4 Days

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Insulin (Drug)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
Boston Children's Hospital
Primary completion
Sep 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
ICU-Free Days
20; 19.4
SECONDARY
90-day Hospital Mortality
52; 40
SECONDARY
28-day Hospital Mortality
47; 32
SECONDARY
Accumulation of Multiple Organ Dysfunction Syndrome (MODS)
326; 324
SECONDARY
Ventilator-Free Days
21.8; 20.9
SECONDARY
Developmental Neurobehavioral Outcomes: VABS-II Composite
79.9; 79.4
SECONDARY
Participants With Device-Related or Non-Device Related Nosocomial Infection
12; 4
SECONDARY
Incidence of Catheter-Associated Bloodstream Infection
1.94; 0
SECONDARY
Incidence of Catheter-Associated Urinary Tract Infection
2.19; 1.79
SECONDARY
Incidence of Ventilator-Associated Pneumonia
0.94; 0
SECONDARY
Incidence of Wound Infection Incidence of Wound Infection
0; 0
SECONDARY
Participants With Severe Hypoglycemia (<40 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety)
5; 6
SECONDARY
Participants With Severe Hypoglycemia (<40 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety)
13; 1
SECONDARY
Participants With Any Hypoglycemia (<60 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety)
26; 29
SECONDARY
Participants With Any Hypoglycemia (<60 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety)
64; 5
SECONDARY
Participants With Hypokalemia (<2.5 mmol/L)
76; 64
SECONDARY
Nursing Workload: SWAT (Subjective Workload Assessment Technique) Instrument
50.0; 36.2
SECONDARY
Nursing Workload: NASA-TLX (National Aeronautics and Space Administration - Task Load Index) Instrument
35.0; 20.4
SECONDARY
Insulin Algorithm Performance: Time to the Target Range
5.5; 1.5
SECONDARY
Insulin Algorithm Performance: Time in the Target Range
57; 91
SECONDARY
Insulin Algorithm Performance: Time-Weighted Glucose Average
109; 123

Summary

Stress hyperglycemia, a state of abnormal metabolism with supra-normal blood glucose levels, is often seen in critically ill patients. Tight glycemic control (TGC) was originally shown to reduce morbidity and mortality in a landmark randomized clinical trial (RCT) of adult critically ill surgical patients but has since come under intense scrutiny due to conflicting results in recent adult trials. One pediatric RCT has been published to date that demonstrated survival benefit but was complicated by an unacceptably high rate of severe hypoglycemia. The Heart And Lung Failure - Pediatric INsulin Titration (HALF-PINT) trial is a multi-center, randomized clinical treatment trial comparing two ranges of glucose control in hyperglycemic critically ill children with heart and/or lung failure. Both target ranges of glucose control fall within the range of "usual care" for critically ill children managed in pediatric intensive care units. The purpose of the study is to determine the comparative effectiveness of tight glycemic control to a target range of 80-110 mg/dL (TGC-1, 4.4-6.1 mmol/L) vs. a target range of 150-180 mg/dL (TGC-2, 8.3-10.0 mmol/L) on hospital mortality and intensive care unit (ICU) length of stay (LOS) in hyperglycemic critically ill children with cardiovascular and/or respiratory failure. This will be accomplished using an explicit insulin titration algorithm and continuous glucose monitoring to safely achieve these glucose targets. Both groups will receive identical standardized intravenous glucose at an age-appropriate rate in order to provide basal calories and mitigate hypoglycemia. Insulin infusions will be titrated with an explicit algorithm combined with continuous glucose monitoring using a protocol that has been safely implemented in 490 critically ill infants and children.

Eligibility Criteria

Inclusion Criteria

  • Cardiovascular failure and/or respiratory failure:
  • Cardiovascular Failure: Dopamine or dobutamine > 5 mcg/kg/min, or any dose of epinephrine, norepinephrine, phenylephrine, milrinone or vasopressin if used to treat hypotension.
  • Respiratory Failure: Acute mechanical ventilation via endotracheal tube or tracheostomy.
  • Age >= 2 weeks and corrected gestational age >= 42 weeks
  • Age 28 days
  • Receiving therapeutic cooling with targeted body temperatures <34 degrees Celsius
  • Current or planned ketogenic diet
  • Ward of the state
  • Pregnancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01565941). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search